Zosano Pharma Corp (NASDAQ:ZSAN) shares saw an uptick in trading volume on Thursday . 9,584,786 shares were traded during mid-day trading, an increase of 217% from the previous session’s volume of 3,022,307 shares.The stock last traded at $0.60 and had previously closed at $0.53.
A number of research firms have commented on ZSAN. ValuEngine raised Zosano Pharma from a “hold” rating to a “buy” rating in a research note on Thursday, April 2nd. BTIG Research cut their price target on Zosano Pharma from $16.00 to $7.00 and set a “buy” rating on the stock in a research note on Friday, March 27th. Maxim Group reaffirmed a “buy” rating and set a $2.00 price target on shares of Zosano Pharma in a research note on Saturday, March 28th. Finally, HC Wainwright initiated coverage on Zosano Pharma in a research note on Thursday. They set a “buy” rating and a $4.00 price target on the stock. Six research analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and an average price target of $4.25.
The firm has a fifty day simple moving average of $0.62 and a 200-day simple moving average of $1.36. The company has a market capitalization of $28.26 million, a P/E ratio of -0.26 and a beta of 2.55. The company has a quick ratio of 0.42, a current ratio of 0.42 and a debt-to-equity ratio of 0.63.
Several large investors have recently bought and sold shares of ZSAN. Oxford Asset Management LLP bought a new position in shares of Zosano Pharma during the fourth quarter worth about $57,000. Ieq Capital LLC bought a new position in shares of Zosano Pharma during the fourth quarter worth about $79,000. UBS Group AG grew its holdings in shares of Zosano Pharma by 93.1% during the fourth quarter. UBS Group AG now owns 68,557 shares of the biotechnology company’s stock worth $105,000 after buying an additional 33,057 shares in the last quarter. Banco Bilbao Vizcaya Argentaria S.A. bought a new position in shares of Zosano Pharma during the fourth quarter worth about $182,000. Finally, Aisling Capital Management LP grew its holdings in shares of Zosano Pharma by 34.0% during the fourth quarter. Aisling Capital Management LP now owns 2,718,226 shares of the biotechnology company’s stock worth $4,132,000 after buying an additional 689,655 shares in the last quarter. Institutional investors and hedge funds own 22.63% of the company’s stock.
Zosano Pharma Company Profile (NASDAQ:ZSAN)
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology. Its lead product candidate is M207, a proprietary formulation of zolmitriptan used for the treatment of migraine.
Further Reading: The Structure of a Futures Contract
Receive News & Ratings for Zosano Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma and related companies with MarketBeat.com's FREE daily email newsletter.